Development of Thiazole-5-carboxylate Derivatives as Selective Inhibitors of Monoacylglycerol Lipase as Target in Cancer
-
Published:2019-02-21
Issue:5
Volume:19
Page:410-423
-
ISSN:1389-5575
-
Container-title:Mini-Reviews in Medicinal Chemistry
-
language:en
-
Short-container-title:MRMC
Author:
Ali Md Rahmat1, Kumar Suresh1, Shalmali Nishtha1, Afzal Obaid1, Azim Sabir1, Chanana Damini1, Alam Ozair1, Paudel Yam Nath2, Sharma Manju2, Bawa Sandhya1
Affiliation:
1. Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi-110062, India 2. Department of Pharmacology, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi-110062, India
Abstract
Introduction: The signalling function of 2-arachidonoylglycerol (2-AG) in endocannabinoid
system is delineated by Monoacylglycerol lipase (MAGL). MAGL readdresses the lipid stores in the
direction of pro-tumorigenic signalling lipids in cancer cells. Selective as well as potent MAGL inhibitors
are limited in number hence their continuous development may lead to a breakthrough invention in
the field of MAGL inhibitors. In succession of the above, we have synthesised 2-amino-4-
methylthiazole-5-carboxylate derivatives and characterised them by collective use of IR, 1H-NMR,
13C-NMR, Mass spectral data and elemental analysis.
</P><P>
Methodology: Thirteen compounds (3c-g, 4c, 4e, 4f and 6b-f) inhibited MAGL with IC50 value 0.037-
9.60 µM. Two compounds (3g and 4c) were found to be most potent with IC50 values 0.037 and
0.063µM, respectively. Thirty synthesised compounds were sent to NCI for anticancer screening, out
of which nine compounds were selected for one dose anticancer assay. Compounds 3g (NSC:788170)
and 4c (NSC:788176)were found to be the most potent during one dose anticancer screening and fulfilled
the specified threshold for growth inhibition criteria of NCI and were further selected for full
panel five dose assay at 10-fold dilutions of five different concentrations.
</P><P>
Conclusion: Compound 3g displayed GI50 value 0.865 μM against EKVX (Non-Small Cell Lung Cancer
cell line), and 1.20 µM against MDA-MB-468 (Breast Cancer cell Line), while (4c) showed GI50
value 0.34 and 0.96 µM against HOP-92 and EKVX (Non-Small Cell Lung Cancer cell line) and 1.08
µM against MDA-MB-231/ATCC(Breast Cancer cell Line). In addition, molecular docking studies of
the said MAGL inhibitors have also been presented in this article.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology,General Medicine
Reference32 articles.
1. Matuszak N, Es-Saadi B, Labar G, Marchand-Brynaert J, Lambert DM. Bioorg Med Chem Lett, Benzisothiazolinone as a useful template for the design of new monoacylglycerol lipase inhibitors: Investigation of the target residues and comparison with octhilinone.,, 2011, 21,, 7321-7324, 2. Aaltonen N, Savinainen JR, Ribas CR, Ronkko J. Chem Biol, Kuusisto.A.; Korhonen.J.; Navia-Paldanius, D.; Hayrinen, J.; Takabe, P.; Kasnanen, H.; Pantsar, T.; Laitinen, T.; Lehtonen, M.; Pasonen-Seppanen, S.; Poso, A.; Nevalainen, T.; Laitinen, J.T. Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase.,, 2013, 20,, 379-390, 3. Tabrizi MA, Baraldi PG, Ruggiero E, Saponaro G, Baraldi S, Romagnoli R, Martinelli A, Tuccinardi T. Eur J Med Chem, Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH).,, 2015, 97,, 289-305, 4. Labar G, Wouters J, Lambert DM. Curr Med Chem, A Review on the monoacylglycerol lipase: At the interface between fat and endocannabinoid signalling.,, 2010, 17,, 2588-2607, 5. Kapanda CN, Masquelier J, Labar G, Muccioli GG, Poupaert JH, Lambert DM. J Med Chem, Synthesis and pharmacological evaluation of 2, 4-Dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors.,, 2012, 55,, 5774-5783,
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|